Technology
Live Price
Offline$4.69
-3.30% today
1Y Change
+107.41%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zepp Health Corporation (ZEPP) is a Technology stock with a market cap of $1.76B and listed on NYSE. The stock last traded around $4.69 and up 107.4% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +36.1%, EPS growth of -728.6%, a dividend yield of 0.0%. What stands out right now is revenue +36.1%, EPS -728.6%, free cash flow -2.3% with operating margin -11.4% and ROIC -6.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZEPP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZEPP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZEPP Max Drawdown
-93.49%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZEPP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.2B
+46.3% YoY
FY Net Income
$136.0M
+146.4% YoY
Free Cash Flow
$71.8M
+119.0% YoY
Revenue Growth
+36.1%
EPS Growth
-728.6%
Gross Margin
38.5%
Net Margin
-15.6%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.8B | 1.3B | 2.5B | 4.2B | 6.2B |
| Gross Profit | 712M | 513M | 654M | 817M | 1.3B |
| Operating Income | -205M | -345M | -216M | -417M | 93M |
| EBITDA | -205M | -346M | -143M | -261M | 201M |
| Net Income | -281M | -554M | -220M | -293M | 136M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 790M | 808M | 995M | 959M | 1.5B |
| Total Assets | 3.9B | 3.9B | 4.5B | 5.2B | 6.1B |
| Total Liabilities | 2.4B | 2.0B | 2.0B | 2.5B | 3.1B |
| Shareholder Equity | 1.5B | 1.8B | 2.5B | 2.6B | 2.9B |
| Total Debt | 1.6B | 1.3B | 1.4B | 1.7B | 1.3B |
| Net Debt | 805M | 521M | 392M | 743M | -160M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
151M
+145.4% YoY
Capital Expenditures
79M
-73.8% YoY
Free Cash Flow
72M
+119.0% YoY
Key ratios
Gross Margin
38.5%
Operating Margin
-11.4%
Net Margin
-15.6%
ROE
-17.9%
Debt / Equity
1.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.